Emerging within the UK, retatrutide, a novel molecule, is sparking considerable excitement within the scientific community regarding its promise for physique management . This dual GIP and GLP-1 target agonist appears to provide a considerable advantage over existing therapies, showing encouraging results in initial clinical studies . Researchers t